While Europe has had a regulatory approval pathway for biosimilar drug products for some years, their use reportedly remains anemic. Physicians are apparently reluctant to prescribe them, despite the lower costs, and companies developing them have evidently had problems recruiting enough subjects for clinical trials and in creating products “similar” enough to the complex reference biotech drugs. According to a press report, Norway will fund clinical studies that switch patients from the original drug to biosimilars in 2014 to demonstrate that the latter are just as effective. Health ministries across Europe will watch the trials closely due to the significant savings that biosimilars offer. The IGES Institut in Berlin has apparently estimated that biosimilar use could save up to 33.4 billion euros (US$45.5 billion) across Europe by 2020. Currently, biosimilars account for less than 0.5 percent of biotechnology drug spending in developed markets, although some countries, such as Germany, provided a stronger market for biosimilars than others. See Reuters, December 3, 2013.